Synlogic
Share
A biotech company focused on new ways to improve treatment for rare metabolic diseases like PKU & HCU
02/12/2024
Last week we announced the decision to end Synpheny-3, our pivotal study in phenylketonuria (PKU), and that as a result, Synlogic will be evaluating strategic options for the company and ceasing operations (see below press release).
We express our sincere appreciation to everyone who has worked for and with Synlogic, as we have advanced science, while building a special company and place to work.
We extend particular gratitude to the PKU & HCU communities, who inspired us, and whose partnership enabled our pursuit of a shared aspiration to bring forward a meaningful new class of medicines. For more information, please read: https://loom.ly/FZtxgso
The Synpheny-3 Clinical Trial is now available in Charleston, SC! Virtual, hybrid, and in-person options for participation are also available.
Scan the QR code to learn more and to speak to Synlogic's clinical trial case manager.
Learn more about our ongoing, pivotal study in in this brief (~2 min) video: https://loom.ly/1Uzqggk or visit pkuresearchstudy.com
Click here to claim your Sponsored Listing.
Category
Website
Address
301 Binney Street, #402
Cambridge, MA
02142
Opening Hours
| Monday | 8am - 5pm |
| Tuesday | 9am - 5pm |
| Wednesday | 9am - 5pm |
| Thursday | 9am - 5pm |
| Friday | 9am - 5pm |
